Skip to content
Open access

DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING UPLC–PDA METHOD FOR SIMULTANEOUS DETERMINATION OF MIRDAMETINIB AND ITS SPECIFIED IMPURITIES

2025 · Journal of Applied Bioanalysis · 0 citations

Abstract

A rapid, sensitive, and reliable reversed-phase UPLC–PDA method was developed and validated for the simultaneous determination of Mirdametinib and its three process-related impurities (Mirdametinib Impurity-1, Impurity-2, and Impurity-3) in pharmaceutical formulations. Chromatographic separation was achieved using a BEH Phenyl column (100 × 2.1 mm, 1.7 µm) with a mobile phase consisting of acetonitrile and 0.1% formic acid buffer adjusted to pH 2.5 using ammonium formate (50:50, v/v). The flow rate was 0.5 mL min⁻¹, injection volume was 5 µL, and detection was performed at 234 nm with a total run time of 5 min. The developed method provided satisfactory separation of Mirdametinib and its impurities, with resolution values of 3.14, 3.78, and 4.29, respectively. The method demonstrated excellent linearity over 50–300 µg mL⁻¹ for Mirdametinib and 1.25–7.50 µg mL⁻¹ for each impurity, with correlation coefficients ≥0.9991. Accuracy was within 98–102%, while precision and intermediate precision showed low variability. The limits of detection were 0.30 µg mL⁻¹ for Mirdametinib and 0.20 µg mL⁻¹ for each impurity, whereas the corresponding limits of quantification were 1.00 and 0.66 µg mL⁻¹, respectively. The method remained robust following deliberate variations in flow rate and mobile-phase composition. Forced degradation studies demonstrated the ability of the method to distinguish Mirdametinib from its degradation products. The developed UPLC–PDA method is therefore suitable for routine quality control and impurity profiling of Mirdametinib pharmaceutical formulations.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.